News articles about BiondVax Pharmaceuticals (NASDAQ:BVXV) have been trending positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a daily sentiment score of 0.37 on Accern’s scale. Accern also assigned news stories about the company an impact score of 50.6902839477748 out of 100, indicating that recent media coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.
Shares of BiondVax Pharmaceuticals (BVXV) traded up $0.06 during trading hours on Friday, reaching $5.85. 6,176 shares of the company’s stock traded hands, compared to its average volume of 47,231. BiondVax Pharmaceuticals has a 1 year low of $3.04 and a 1 year high of $10.75.
Separately, ValuEngine downgraded shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd.
About BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.